Stempoint Capital LP Raises Stock Holdings in Pharvaris N.V. $PHVS

Stempoint Capital LP increased its stake in shares of Pharvaris N.V. (NASDAQ:PHVS) by 48.4% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,637 shares of the company’s stock after purchasing an additional 28,248 shares during the quarter. Stempoint Capital LP owned approximately 0.13% of Pharvaris worth $2,447,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in PHVS. GF Fund Management CO. LTD. purchased a new position in Pharvaris in the 4th quarter valued at about $35,000. Barclays PLC purchased a new stake in shares of Pharvaris during the fourth quarter worth about $77,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Pharvaris in the fourth quarter valued at approximately $86,000. JPMorgan Chase & Co. raised its position in shares of Pharvaris by 30.6% in the second quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after buying an additional 783 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Pharvaris in the fourth quarter valued at approximately $110,000.

Wall Street Analysts Forecast Growth

PHVS has been the topic of a number of analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research report on Friday, July 17th. Citigroup reiterated a “buy” rating on shares of Pharvaris in a report on Wednesday, April 15th. Wedbush raised their price objective on Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a report on Tuesday, April 7th. UBS Group set a $74.00 price objective on Pharvaris in a research report on Wednesday, May 13th. Finally, Royal Bank Of Canada reduced their target price on Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $50.08.

Pharvaris Stock Down 3.1%

Shares of PHVS opened at $32.62 on Thursday. Pharvaris N.V. has a fifty-two week low of $19.12 and a fifty-two week high of $36.60. The company’s fifty day moving average is $32.71 and its two-hundred day moving average is $29.45. The firm has a market cap of $2.13 billion, a PE ratio of -10.26 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.70) EPS for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. As a group, equities research analysts anticipate that Pharvaris N.V. will post -2.97 earnings per share for the current year.

Insider Activity

In other news, insider Anna Nijdam sold 2,670 shares of Pharvaris stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $30.87, for a total value of $82,422.90. Following the transaction, the insider directly owned 46,275 shares of the company’s stock, valued at $1,428,509.25. The trade was a 5.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Berndt Modig sold 2,291 shares of Pharvaris stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $31.07, for a total value of $71,181.37. Following the completion of the transaction, the chief executive officer directly owned 135,209 shares in the company, valued at $4,200,943.63. This represents a 1.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 178,322 shares of company stock valued at $5,969,286 in the last 90 days. 11.84% of the stock is owned by corporate insiders.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.